Organization for Rare Disorders Honors Industry Innovators, Medical Trailblazers, and Patient Advocates at the 2026 Rare Impact Awards
WASHINGTON, D.C. — The National Organization for Rare Disorders (NORD®) has announced its distinguished roster of honorees for the annual NORD Rare Impact Awards®, recognizing a diverse group of biopharma industry leaders, medical scientists, patient advocates, and community champions. The awards celebrate individuals and organizations whose exceptional contributions have measurably improved the lives of the more than 30 million Americans living with a rare disease.

The 2026 honorees encompass a broad spectrum of the rare disease ecosystem. They include innovative pharmaceutical and biotechnology companies whose recent treatments have transformed patient outcomes, community leaders working tirelessly to raise awareness, trailblazing researchers pushing the boundaries of medical science, and advocates spearheading critical legislative and regulatory changes across the United States.
The announcement underscores both the triumphs and the ongoing challenges of the rare disease sector, where an estimated 95% of the more than 10,000 known rare diseases still lack an approved therapeutic option.

"With approximately 95% of more than 10,000 known rare diseases still lacking an approved treatment, advancing scientific progress is critical," said Pamela K. Gavin, NORD Chief Executive Officer. "NORD is proud to honor these companies and nonprofit organizations for pioneering new therapies and advancing research that can change what is possible for individuals and families affected by these rare diseases. Their progress in addressing the unique challenges of these conditions is also contributing knowledge, approaches, and breakthroughs that help move science and the entire rare disease field forward."
Industry Innovators in Rare Disease
Among this year’s notable honorees are five pioneering companies and one nonprofit organization that, alongside impacted patient communities, celebrated recent U.S. Food and Drug Administration (FDA) approvals for first-of-their-kind rare disease therapies.

Mighty Therapeutics is being recognized for FORZINITY™, the first-ever therapy approved for Barth syndrome, a very rare, progressive, and life-limiting genetic disease affecting cellular mitochondria. Clinical data has shown the treatment improves muscle strength and quality of life for patients. Barth syndrome advocates, including NORD Member the Barth Syndrome Foundation, spent over a decade pushing for its development and helping secure its accelerated approval. The introduction of FORZINITY brings renewed hope not only to Barth families but also to the broader rare mitochondrial disease community, which has lauded the decision as a major milestone for advancing research and regulatory pathways.
UCB is being honored for KYGEVVI®, the first and only FDA-approved treatment for adults and children with thymidine kinase 2 deficiency (TK2d) whose symptoms began at or before 12 years of age. Clinical findings demonstrated that KYGEVVI reduced the risk of death by over 90%, with 75% of patients regaining at least one previously lost motor skill and many successfully reducing or eliminating their need for ventilatory support. The approval was celebrated by NORD Members the United Mitochondrial Disease Foundation, MitoAction, and the Muscular Dystrophy Association, all of which spent years investing heavily in foundational mitochondrial disease research.

Fondazione Telethon has earned recognition for Waskyra™, a breakthrough gene therapy for Wiskott-Aldrich syndrome (WAS). Developed through decades of rigorous research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, WAS is a genetically inherited type of primary immunodeficiency (PI) and the first PI to receive an FDA-approved gene therapy. Furthermore, Waskyra marks a historic milestone as the first time a nonprofit organization has successfully developed and brought to market an FDA-approved gene therapy. The achievement was widely celebrated by NORD Member the Immune Deficiency Foundation.
Omeros is being recognized for YARTEMLEA®, the first and only FDA-approved treatment for adults and children two years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This condition is a severe and frequently fatal complication of stem cell transplantation resulting from endothelial cell injury, which causes blood clots in small blood vessels and subsequent damage to vital organs. Bone marrow transplant advocacy groups and specialized medical institutions have hailed YARTEMLEA as a targeted and potentially life-saving therapeutic option.

Jazz Pharmaceuticals is being honored for MODEYSO™, the first and only FDA-approved treatment for recurrent H3K27M-mutant diffuse midline glioma (DMG), one of the most aggressive and devastating brain tumors impacting children and young adults. Every year, approximately 2,000 Americans and their families receive this harrowing rare cancer diagnosis. The patient and research community spent more than a decade funding and participating in the foundational studies that made the breakthrough possible. By securing accelerated approval for a new treatment pathway, Jazz Pharmaceuticals has offered patients and their families the possibility of a new future.
Verastem Oncology rounds out the industry innovator category with the AVMAPKI® FAKZYNJA® CO-PACK, the first treatment specifically approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This rare form of cancer carries an exceptionally high unmet medical need, with fewer than 14% of patients responding to traditional chemotherapy and hormone therapy. With a demonstrated response rate of 44%, the administration of the co-pack alongside routine molecular testing for KRAS is expected to establish a new standard of care for LGSOC in the near future.

Individuals and Organizations Honored
In addition to celebrating biopharmaceutical innovation, NORD is recognizing the outstanding contributions of individuals and organizations dedicated to improving life for the one in 10 Americans living with a rare disorder.
The Foundation for Prader-Willi Research (FPWR) is the recipient of the Abbey S. Meyers Leadership Award. An active NORD Member, FPWR leads patient-centered research into Prader-Willi syndrome (PWS) through its Global PWS Registry, which was constructed using NORD’s IAMRARE® patient registry platform. Insights derived from this registry directly contributed to last year’s landmark FDA approval of VYKAT™ XR, the first approved treatment to address excessive hunger in adults and children with PWS, which is one of the disorder’s hallmark challenges. This milestone marked the first known instance of IAMRARE data directly contributing to an FDA approval.

Dr. Stephanie E. Haridopolos has been awarded the Policy Changemaker Award. A board-certified family medicine physician and prominent public health official, Dr. Haridopolos has built a distinguished career spanning clinical practice and high-level government service. Serving initially as Chief of Staff of the Office of the Surgeon General and subsequently as its Director of National Health Communications, she has been a vital advocate for rare disease patients. Most notably, she helped facilitate the U.S. Department of Health and Human Services’ addition of Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Newborn Screening Panel (RUSP). Since May 2026, Dr. Haridopolos has performed the interim duties of the Surgeon General in the absence of a Senate-confirmed nominee.
Dr. Julieta Bonvin Sallago of Connecticut is the recipient of a Community Champion Award. An international medical graduate who lives with a rare disease herself, she is pursuing a career as a genetic counselor in the United States and works in clinical trial recruitment at Connecticut Children’s Hospital for the Glycogen Storage Disease Program—the exact family of disorders for which she was diagnosed. Dr. Sallago has leveraged her scientific and cultural expertise to become a leader within NORD’s volunteer community, supporting the planning and execution of Latino patient and family listening sessions, translating NORD Rare Disease Reports into Spanish, and serving on the advisory committee for the NORD® Living Rare Study.

Lily Emmanuel of Colorado has also received a Community Champion Award. A passionate advocate and volunteer leader, she works to expand rare disease awareness and strengthen community connections across the western United States. Through her leadership with NORD Running for Rare® in Colorado, Emmanuel has created inclusive opportunities for individuals impacted by rare disorders to engage in advocacy and fundraising through wellness initiatives, forging vital relationships with hospitals, nonprofits, and local running groups.
Dr. Maureen Helgren of Connecticut has been recognized with a Community Champion Award for transforming rare disease education by integrating it into the core curriculum at the Frank H. Netter, MD School of Medicine at Quinnipiac University. She developed a dedicated rare disease course, founded the annual Netter Rare Disease Symposium, and regularly invites patients and advocates into the classroom. Serving as faculty advisor for the university’s NORD Students for Rare® chapter, Dr. Helgren helps students participate in NORD’s annual Rare Diseases and Orphan Products Breakthrough Summit® in Washington, D.C., thereby reducing diagnostic delays and fostering fierce patient advocacy among future physicians.

Dr. Susan A. Berry of Minnesota is a recipient of the Medical & Scientific Trailblazer Award. Her career at the University of Minnesota Medical School NORD Rare Disease Center of Excellence exemplifies excellence in advancing rare disease research, diagnosis, and care at scale. Her work on inborn errors of metabolism, conducted in collaboration with advocates like the National PKU Alliance, has defined a vital model of care. Nationally, Dr. Berry has served as an advisor on newborn screening policies and an advocate for medical foods, while also lending her expertise to NORD’s Board of Directors and Scientific & Medical Advisory Committee.
Dr. Stephen Kingsmore of California has also received a Medical & Scientific Trailblazer Award. As Founding President and CEO of the Rady Children’s Institute for Genomic Medicine, a NORD Rare Disease Center of Excellence, Dr. Kingsmore has pioneered whole genome sequencing, established rapid genetic testing as a standard clinical tool, and developed the first comprehensive genomic carrier screening test. Recognizing that approximately 80% of rare diseases are genetic in origin, he continues working to expand precision medicine through emerging digital platforms.

Mark Skinner, JD, of New York has been honored with the Lifetime Achievement Award for his extensive history of leadership in bleeding disorders advocacy locally, nationally, and globally. Skinner has led the World Federation of Hemophilia and the National Bleeding Disorders Foundation, and has served on critical advisory panels including the U.S. Health and Human Services Advisory Committee on Blood and Tissue Safety and Availability. A champion of patient-centered outcomes research, he has elevated patient voices across all rare disease categories through his service on NORD’s Board of Directors and related national research boards.
Paridhi Tyagi of New Jersey is the recipient of the Youth Leadership Award. During her high school sophomore year, Tyagi founded a genetics club and partnered with NORD Students for Rare to educate her peers. For Rare Disease Day 2024, she organized a library awareness display and shared patient stories over school announcements. Furthermore, she established a collaboration with Girl Scouts USA focused on genetics and rare disease education, hosting workshops that taught participants about inclusion and foundational science through hands-on activities. Her efforts culminated in her attendance at the NORD Breakthrough Summit as the sole high school student participating in professional-level programming.

"Each of these 2026 Rare Impact Award winners demonstrates the power we each have as individuals to drive change in our communities, whether that’s as an advocate, policymaker, scientist, or physician," Gavin concluded. "They inspire us all to persevere in our shared mission to alleviate the physical, emotional, and financial strain that rare diseases place on too many individuals and families."
The Community Champion, Policy Changemaker, Youth Leader, Lifetime Achievement, and Abbey S. Meyers Leadership Awardees are being recognized in person at the NORD Breakthrough Summit® in Washington, D.C. The Scientific and Medical Trailblazer Awardees were honored earlier this year at the NORD® Rare Disease Scientific Symposium, and NORD CEO Pamela Gavin is presenting the Industry Innovation Awards directly to each recipient company and their staff at their respective U.S. headquarters.

Further information regarding the 2026 Rare Impact Awards is available at rareimpact.org.
